论文部分内容阅读
目的观察依达拉奉联合舒血宁治疗急性脑梗死的临床疗效。方法140例脑梗死患者随机分为2组,对照组70例采用舒血宁治疗,观察组70例在对照组基础上加用依达拉奉治疗,14 d后评定疗效。结果观察组和对照组的总有效率分别为88.57%和71.43%,2组比较P<0.05,差异有统计学意义。结论依达拉奉联合舒血宁治疗急性脑梗死可提高疗效,且安全性高。
Objective To observe the clinical efficacy of edaravone and shuxuening in the treatment of acute cerebral infarction. Methods One hundred and forty patients with cerebral infarction were randomly divided into two groups. 70 patients in the control group were treated with Shuxuening, and 70 patients in the observation group were treated with edaravone on the basis of the control group. The therapeutic effect was evaluated after 14 days. Results The total effective rate of observation group and control group were 88.57% and 71.43%, respectively, P <0.05 in two groups, the difference was statistically significant. Conclusion Edaravone combined with Shuxuening treatment of acute cerebral infarction can improve the efficacy and safety.